Flutamide
Flutamide (flutamide) is a small molecule pharmaceutical. Flutamide was first approved as Eulexin on 1989-01-27. It is used to treat hirsutism and prostatic neoplasms in the USA. The pharmaceutical is active against androgen receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Flutamide (discontinued: Eulexin, Flutamide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Flutamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EULEXIN | Merck & Co | N-018554 DISCN | 1989-01-27 | 1 products, RLD |
Hide discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| prostatic neoplasms | — | D011471 | C61 |
| hirsutism | HP_0001007 | D006628 | L68.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0175 | Flutamide, oral, 125 mg |
Clinical
Clinical Trials
77 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 6 | 23 | 32 | 3 | 4 | 64 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | — | — | 1 | — | 1 |
| Congenital adrenal hyperplasia | D000312 | — | E25.0 | — | — | — | 1 | — | 1 |
| Adrenogenital syndrome | D047808 | — | E25.9 | — | — | — | 1 | — | 1 |
| Adrenocortical hyperfunction | D000308 | EFO_1000797 | — | — | — | — | 1 | — | 1 |
| Premenstrual dysphoric disorder | D065446 | — | F32.81 | — | — | — | 1 | — | 1 |
| Premenstrual syndrome | D011293 | — | N94.3 | — | — | — | 1 | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | 1 | — | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | — | 4 | 4 | — | — | 7 |
| Neoplasms | D009369 | — | C80 | — | 1 | 2 | — | — | 2 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | — | 1 | — | — | 1 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | — | 1 | — | — | 1 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 1 | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | 1 | — | — | 1 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | 1 | — | — | 1 |
| Hot flashes | D019584 | — | — | — | — | 1 | — | — | 1 |
| Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
| Prostatic intraepithelial neoplasia | D019048 | — | N42.31 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 2 | 1 | — | — | 3 | 6 |
| Hyperandrogenism | D017588 | — | — | — | 1 | — | — | 1 | 2 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | 1 | — | — | 1 | 2 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
| Infertility | D007246 | HP_0000789 | — | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Flutamide |
| INN | flutamide |
| Description | Flutamide is a monocarboxylic acid amide and a member of (trifluoromethyl)benzenes. It has a role as an androgen antagonist and an antineoplastic agent. |
| Classification | Small molecule |
| Drug class | non-steroid antiandrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 13311-84-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL806 |
| ChEBI ID | 5132 |
| PubChem CID | 3397 |
| DrugBank | DB00499 |
| UNII ID | 76W6J0943E (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Flutamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,896 documents
View more details
Safety
Black-box Warning
Black-box warning for: Eulexin, Flutamide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,056 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use